These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32888388)

  • 1. The new landscape of retinal gene therapy.
    Ku CA; Pennesi ME
    Am J Med Genet C Semin Med Genet; 2020 Sep; 184(3):846-859. PubMed ID: 32888388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
    Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.
    Lee K; Garg S
    Genet Med; 2015 Apr; 17(4):245-52. PubMed ID: 25790163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
    Maguire AM; Bennett J; Aleman EM; Leroy BP; Aleman TS
    Mol Ther; 2021 Feb; 29(2):442-463. PubMed ID: 33278565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy in Retinal Dystrophies.
    Ziccardi L; Cordeddu V; Gaddini L; Matteucci A; Parravano M; Malchiodi-Albedi F; Varano M
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies.
    Garanto A
    Adv Exp Med Biol; 2019; 1185():71-77. PubMed ID: 31884591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Gene Therapy Treatments for Inherited Retinal Diseases.
    Bakall B; Hariprasad SM; Klein KA
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):472-478. PubMed ID: 30021033
    [No Abstract]   [Full Text] [Related]  

  • 9. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
    [No Abstract]   [Full Text] [Related]  

  • 10. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
    Kang C; Scott LJ
    Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
    Weng CY
    Ophthalmol Retina; 2019 May; 3(5):450. PubMed ID: 31044739
    [No Abstract]   [Full Text] [Related]  

  • 12. [RPE65-retinal Dystrophies: From the Spectrum of the Clinical Picture to Gene Therapy].
    Stingl K; Priglinger C
    Klin Monbl Augenheilkd; 2024 Mar; 241(3):257-258. PubMed ID: 38508213
    [No Abstract]   [Full Text] [Related]  

  • 13. Dog models for blinding inherited retinal dystrophies.
    Petersen-Jones SM; Komáromy AM
    Hum Gene Ther Clin Dev; 2015 Mar; 26(1):15-26. PubMed ID: 25671556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec.
    Stingl K; Priglinger C; Herrmann P
    Klin Monbl Augenheilkd; 2024 Mar; 241(3):259-265. PubMed ID: 38508214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
    Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
    Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
    Bennett J; Maguire AM
    Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of
    Kahraman NS; Öner A; Özkul Y; Dündar M
    Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.
    Pulman J; Sahel JA; Dalkara D
    CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
    Pierce EA; Bennett J
    Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.